Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02180724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02180724 · ClinicalTrials.gov record · last posted 2026-06-16

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Name: An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia — clinical trial record (NCT02180724)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorAcerta Pharma BV

Started2014-09-11

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

Amendment record 23 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 23 times since 2014-07-01; most recent amendment 2026-06-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2016-01-18

Status change Recruiting→Active, Not Recruitingv4

2014-08-04

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT02180724
Lead Sponsor	Acerta Pharma BV
Conditions	Waldenström Macroglobulinemia (WM)
Enrollment	107 participants
Start Date	2014-09-11
Primary Completion	2019-10-01 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-16